Information:
Error:
Keywords
Pharmacology ×
- Clinical Trial (43)
- Psychiatry (39)
- Bipolar Disorder (38)
- Adverse event (4)
- Electrocardiogram (ECG) (4)
- Vital Signs (3)
- Physical Examination (2)
- Polysomnography (2)
- Clinical Trial, Phase II (2)
- Blood (2)
- General Practitioners (2)
- Clinical Laboratory Services (2)
- Patient information (2)
- Eligibility Determination (2)
- Hypersensitivity (2)
- Sleep Initiation and Maintenance Disorders (2)
- Medical History Taking (2)
- Appetite Depressants (1)
- Pharmacokinetics (1)
- Physical Fitness (1)
- Pregnancy (1)
- Skin (1)
- Social Identification (1)
- Transcranial Magnetic Stimulation (1)
- Child (1)
- Tobacco Use (1)
- On-Study Form (1)
- Concomitant Medication (1)
- Trial screening (1)
- End of Study (1)
- Demography (1)
- Alcohol Drinking (1)
- Doxorubicin (1)
- Drug Administration Schedule (1)
- Electroencephalography (1)
- Exanthema (1)
- Family (1)
- Neoplasms (1)
- Neurologic Examination (1)
- Nutritional Status (1)
- Obesity (1)
Table of contents
Selected data models
You must log in to select data models for download or further analysis.
43 Search results.
Itemgroups: Physical Examination, Determination of cardiac function (before sampling period), Clinical chemistry, Haematology, Agents that are known to interact with doxorubicin according to SmPCs administered?, Antiemetic agents administered?, Cardioprotective agents administered?, Systemic antimycotic agents, Other agents administered?, Actual protocol block, Start of actual protocol block, Chemotherapy in actual protocol block administered ?, Previous anthracycline treatment, Doxorubicin treatment in 1st sampling period, Haematological toxicity of actual protocol block, Transfusions, Determination of cardiac function (end of sampling period), Adverse events, Start of next protocol block, Footer module
Registration
6 itemgroups 25 items Itemgroups: Administrative Data, ECG Abnormalities, Rhythm, P-Wave and QRS Morphology, Conduction, Myocardial Infarction, Depolarisation/Repolarisation (QRS-T), Other Abnormalities
Itemgroups: Administrative Data, Dermatological/Hypersensitivity Adverse Event, Systemic Symptoms, Signs or Laboratory Abnormalities, Haematologic Abnormalities, Supportive/Investigative Measures, Diagnosis, Responsible for Diagnosis, Lesion Location, Concomitant Medication, Infections, Conclusion
Itemgroups: Administrative Data, Dosing date/time, Predose pharmacodynamic sample
Itemgroups: Administrative Data, Investigational Product, Treatment Confirmation
Itemgroups: Administrative Data, Neurological Examination, Neurological Examination Results, Neurological Examination Conclusion
Itemgroups: Administrative Data, Concomitant Medication, Concomitant Medication Details, Conclusion
Itemgroups: Administrative Data, 12-Lead Electrocardiogram
Itemgroups: Administrative Data, Unscheduled 12-Lead Electrocardiogram
Itemgroups: Administrative Data, 12-Lead Electrocardiogram, Conclusion
Itemgroups: Administrative Data, Serious Adverse Event, SECTION 1: Serious Adverse Event Record, SECTION 2: Seriousness, SECTION 3: Demography Data, SECTION 4: Serious Adverse Event Recurrence, SECTION 5: Causes of SAE, SECTION 6: Relevant Medical Conditions, SECTION 7: Other Relevant Risk Factors, SECTION 8: Relevant Concomitant Medications, SECTION 9: Details of Investigational Product(s), SECTION 10: Details of Relevant Assessments, SECTION 11: Narrative Remarks, Conclusion, SECTION 12: Additional/Follow-Up Information
Itemgroups: Administrative Data, Mother's relevant medical/family history, Father's Relevant Medical/Family History, Drug Exposures, Study Withdrawal, Reporting Investigator Information